Neuronal nicotinic acetylcholine receptor alpha-6 beta-2 (alpha6beta2 nAChR)

The Neuronal nicotinic acetylcholine receptor alpha-6 beta-2 (alpha6beta2) is a subtype of pentameric ligand-gated ion channels primarily expressed in the dopaminergic neurons of the substantia nigra and ventral tegmental area [1][2]. It plays a critical role in modulating dopamine release in the striatum, making it a key regulator of the brain's reward system and motor control [3]. Due to its restricted expression pattern compared to the more ubiquitous alpha4beta2 subtype, it is considered a high-value therapeutic target for treating Parkinson's disease and nicotine addiction with potentially fewer side effects [2][4]. In Parkinson's disease, alpha6-containing receptors are among the first to be lost, and their preservation or activation is a strategy for neuroprotection and symptomatic relief [3]. Conversely, because they mediate the reinforcing effects of nicotine, antagonists or partial agonists are explored for smoking cessation [4]. Pharmacological targeting of alpha6beta2 remains challenging due to the high structural similarity between different nAChR subunits, requiring highly selective ligands like certain conotoxins or novel small molecules [1][5]. Sources: [1] UniProt Consortium. "CHRNA6 - Neuronal acetylcholine receptor subunit alpha-6." [2] Gotti, C., et al. (2009). "Nicotinic acetylcholine receptors in the mesocorticolimbic dopaminergic system." Progress in Neurobiology. [3] Quik, M., et al. (2011). "Nicotinic receptors as targets for drug development in Parkinson's disease." Movement Disorders. [4] Yang, K., et al. (2011). "Alpha6-containing nicotinic receptors: a target for nicotine addiction." Journal of Molecular Neuroscience. [5] McIntosh, J. M., et al. (2004). "Alpha6-containing nicotinic acetylcholine receptors: localized expression and role in stimulating dopamine release." Molecular Pharmacology.

Other names

CHRNA6-CHRNB2 receptoralpha6beta2 nicotinic receptoralpha6* nAChRCholinergic receptor nicotinic alpha 6 beta 2

Agonism, partial agonism, or antagonism of the ligand-gated cation channel to modulate neuronal excitability and neurotransmitter release.